(S)-AMPA: Properties, Mechanisms & Lab Use FAQs

(S)-AMPA is a potent, stereochemically defined, selective agonist of AMPA-subtype ionotropic glutamate receptors widely used as a pharmacological tool in neuroscience research to dissect excitatory synaptic transmission.

Full chemical name

(S)-2-Amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propanoic acid

Receptor target

AMPA-subtype ionotropic glutamate receptors (GluA1–GluA4)

Stereochemistry

Single (S)-enantiomer; the (R)-enantiomer is essentially inactive at AMPA receptors

Solubility

Soluble in water and dilute aqueous base; sparingly soluble in organic solvents

Molecular weight

186.19 g/mol

Primary research use

Pharmacological activation of AMPA receptors to study synaptic plasticity, LTP, and excitatory neurotransmission

What Is (S)-AMPA and Why Is Stereochemistry Important?

(S)-AMPA, formally (S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propanoic acid, is the biologically active enantiomer of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid). It is classified as a selective agonist of AMPA-subtype ionotropic glutamate receptors, which mediate the majority of fast excitatory synaptic transmission in the mammalian central nervous system.

Stereochemistry is critical to receptor activity. The (S)-configuration allows optimal fitting within the orthosteric binding cleft of AMPA receptor subunits (GluA1–GluA4), producing channel opening and sodium/potassium flux. The (R)-enantiomer lacks meaningful agonist activity at these receptors. Researchers should therefore confirm enantiomeric purity when sourcing the compound, as racemic material will deliver approximately half the expected pharmacological potency.

AMPA receptors are tetrameric ligand-gated ion channels assembled from combinations of GluA1–GluA4 subunits. Their subunit composition influences calcium permeability, kinetics, and sensitivity to auxiliary proteins such as TARPs, all of which can be probed using (S)-AMPA as a tool compound.

Mechanism of Action at AMPA Receptors

(S)-AMPA binds to the ligand-binding domain (LBD) of AMPA receptor subunits in a clam-shell fashion, inducing domain closure that drives conformational changes in the transmembrane domain and gate opening. The resulting cation influx — primarily Na⁺, with K⁺ efflux — depolarises the postsynaptic membrane.

Unlike NMDA receptors, most AMPA receptor complexes are calcium-impermeable under physiological conditions due to the presence of the GluA2 subunit, which undergoes RNA editing (Q/R site) to insert an arginine residue in the channel pore. GluA2-lacking AMPA receptors, however, are calcium-permeable and particularly relevant in certain interneurons and in pathological states. (S)-AMPA activates both calcium-permeable and calcium-impermeable AMPA receptor populations non-selectively with respect to calcium permeability.

(S)-AMPA does not significantly activate NMDA receptors or kainate receptors at concentrations typically used in research, making it a valuable tool for isolating AMPA receptor-mediated currents when used in conjunction with appropriate pharmacological blockers (e.g., AP5 for NMDA receptors).

Preparation, Storage, and Handling Guidelines

Reconstitution: (S)-AMPA is best dissolved in ultrapure water or phosphate-buffered saline (PBS, pH 7.4). For concentrations above the aqueous solubility limit, prepare a stock in dilute NaOH (e.g., 0.1 M) and then dilute to the working concentration with physiological buffer. Avoid prolonged exposure to strongly acidic or basic conditions, which may lead to degradation.

Stock concentration: A stock solution of 10–100 mM in water is typically practical. Aliquot to avoid repeated freeze-thaw cycles, which can reduce compound integrity over time.

Storage: Store the solid and solutions at –20 °C, protected from light and moisture. Under these conditions, the compound is expected to be stable for extended periods, though users should verify stability with their specific formulation. Allow the vial to reach room temperature before opening to prevent condensation.

Safety: (S)-AMPA is a potent neuroexcitatory agent. Avoid inhalation of dust and direct skin or mucous membrane contact. Handle in a well-ventilated fume hood and wear appropriate PPE (gloves, lab coat, eye protection). Consult the Safety Data Sheet (SDS) provided with the product before use.

Key Research Applications of (S)-AMPA

(S)-AMPA is employed across a broad range of neuroscience research applications:

• Electrophysiology: Applied exogenously (bath application or focal microperfusion) to evoke AMPA receptor-mediated currents in patch-clamp or sharp-electrode recordings from neurons or heterologous expression systems (e.g., Xenopus oocytes, HEK293 cells).
• Synaptic plasticity studies: Used to probe long-term potentiation (LTP) and long-term depression (LTD) by manipulating AMPA receptor activation levels and studying receptor trafficking.
• Receptor characterisation: Concentration-response curves generated with (S)-AMPA allow calculation of EC₅₀ values for wild-type and mutant AMPA receptor subunits, aiding structure-function studies.
• In vivo pharmacology: Administered intracerebrally or intrathecally to study excitatory neurotransmission in animal models; dose must be carefully controlled given the excitotoxic potential at high concentrations.
• Drug screening: Used as a reference agonist in assays designed to identify AMPA receptor modulators (positive allosteric modulators, antagonists).

When designing experiments, researchers should include appropriate controls such as the competitive AMPA/kainate receptor antagonist CNQX or the selective AMPA receptor antagonist NBQX to confirm receptor specificity of observed responses.

Quality, Purity, and Ordering Information

Aladdin Scientific supplies (S)-AMPA (SKU: A276612) as a research-grade reagent. For pharmacological and electrophysiological applications, high enantiomeric purity (typically ≥98% ee) and high chemical purity are essential to ensure reproducible results. Users are encouraged to request a certificate of analysis (CoA) confirming purity by HPLC and enantiomeric excess.

The compound is available in standard pack sizes suitable for research laboratories. For bulk quantities or custom specifications, contact Aladdin Scientific technical sales. Pricing, availability, and current stock status are accessible through the Aladdin Scientific online catalogue.

For questions regarding compatibility with specific assay formats, formulation advice, or technical support, contact the Aladdin Scientific technical support team. Return and refund policies follow Aladdin Scientific standard terms; please review these on the website prior to purchase.

Frequently asked questions

What makes (S)-AMPA selective for AMPA receptors over other glutamate receptor subtypes?

(S)-AMPA was historically the defining ligand from which AMPA receptors derived their name, and its molecular structure complements the orthosteric binding site of GluA1–GluA4 subunits with high affinity. At concentrations commonly used in research, it shows substantially lower potency at kainate and NMDA receptors, enabling selective AMPA receptor activation when appropriate control experiments are included. Researchers should still include antagonists such as NBQX to pharmacologically confirm receptor identity.

How should I prepare a stock solution of (S)-AMPA for electrophysiology experiments?

Dissolve (S)-AMPA in ultrapure water or PBS (pH 7.4) to make a concentrated stock, typically 10–50 mM. If solubility is limiting, add a minimal volume of 0.1 M NaOH to aid dissolution, then adjust pH before use. Aliquot the stock solution and store at –20 °C to avoid repeated freeze-thaw cycles. Dilute to the desired working concentration (commonly 1 µM–1 mM depending on the application) in your extracellular recording solution immediately before use.

Can (S)-AMPA be used in vivo, and what precautions are necessary?

Yes, (S)-AMPA can be administered in vivo via intracerebral, intracerebroventricular, or intrathecal routes to study excitatory neurotransmission in animal models. However, because high local concentrations of AMPA receptor agonists can cause excitotoxic neuronal death, dosing must be carefully titrated and pilot dose-finding experiments are strongly recommended. Institutional animal ethics approval and adherence to relevant regulations are required. Vehicle controls and receptor-specific antagonists should be included in the experimental design to confirm on-target effects.

What is the difference between (S)-AMPA and the racemic AMPA mixture?

Racemic AMPA contains equimolar amounts of the (S)- and (R)-enantiomers. Since the (R)-enantiomer is essentially inactive at AMPA receptors, a racemic preparation delivers approximately half the effective agonist content compared with the pure (S)-enantiomer at the same nominal concentration. For quantitative pharmacology, dose-response studies, and precise EC₅₀ determinations, the enantiopure (S)-form is strongly preferred to avoid ambiguity in data interpretation.

What antagonists should I use alongside (S)-AMPA to confirm receptor specificity?

NBQX (2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide) is a widely used, highly selective competitive AMPA receptor antagonist suitable for blocking (S)-AMPA-evoked responses. CNQX is another option that blocks both AMPA and kainate receptors. To isolate AMPA receptor-specific currents in the presence of other glutamate receptor activity, combine NBQX with AP5 (D-APV) to block NMDA receptors simultaneously. These controls are standard practice in the field.

References

1. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev. 1999;51(1):7–61. PMID:10049997
2. Traynelis SF, Wollmuth LP, McBain CJ, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev. 2010;62(3):405–496. doi:10.1124/pr.109.002451
3. Hollmann M, Heinemann S. Cloned glutamate receptors. Annu Rev Neurosci. 1994;17:31–108. doi:10.1146/annurev.ne.17.030194.000335
4. Collingridge GL, Olsen RW, Peters J, Spedding M. A nomenclature for ligand-gated ion channels. Neuropharmacology. 2009;56(1):2–5. doi:10.1016/j.neuropharm.2008.06.063

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.